Geneva, Dec. 23 -- International Clinical Trials Registry received information related to the study (ACTRN12625001382460) titled 'STATEsMAN- A Phase 2 trial of SaciTuzumAb TirumotEcan (sac-TMT) in patients with MetastAtic castration resistant prostate cancer (mCRPC)' on Dec. 9.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Type of endpoint: Efficacy
Primary Sponsor: Metro South Hospital and Health Services
Condition:
Metastatic castration resistant prostate cancer
Prostate Cancer
Metastatic castration resistant prostate cancer
Prostate Cancer
Cancer - Prostate
Renal and Urogenital - Other renal and urogenital disorders
Intervention:
STATEsMAN will see...